.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Cantor Fitzgerald
Deloitte
Express Scripts
Citi
Chinese Patent Office
Teva
US Army
Boehringer Ingelheim
McKesson

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,565,874 protect, and when does it expire?


Patent ► Subscribe protects ELIGARD and is included in four NDAs.

This patent has fifty-seven patent family members in twenty-six countries.

Summary for Patent: ► Subscribe

Title: Polymeric delivery formulations of leuprolide with improved efficacy
Abstract:The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.
Inventor(s): Dunn; Richard L. (Fort Collins, CO), Garrett; John Steven (Fort Collins, CO), Ravivarapu; Harish (Union City, CA), Chandrashekar; Bhagya L (Fort Collins, CO)
Assignee: Atrix Laboratories (Fort Collins, CO)
Application Number:09/711,758
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Tolmar Therap
ELIGARD
leuprolide acetate
INJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004RXYesYes► Subscribe► SubscribeY METHOD OF TREATING CANCER
Tolmar Therap
ELIGARD
leuprolide acetate
INJECTABLE;SUBCUTANEOUS021343-001Jan 23, 2002RXYesYes► Subscribe► SubscribeY METHOD OF TREATING CANCER
Tolmar Therap
ELIGARD
leuprolide acetate
INJECTABLE;SUBCUTANEOUS021379-001Jul 24, 2002RXYesYes► Subscribe► SubscribeY METHOD OF TREATING CANCER
Tolmar Therap
ELIGARD
leuprolide acetate
INJECTABLE;SUBCUTANEOUS021488-001Feb 13, 2003RXYesYes► Subscribe► SubscribeY METHOD OF TREATING CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,314 Controlled release liquid delivery compositions with low initial drug burst► Subscribe
8,486,455Polymeric delivery formulations of leuprolide with improved efficacy► Subscribe
8,470,359Sustained release polymer► Subscribe
6,773,714 Polymeric delivery formulations of leuprolide with improved efficacy► Subscribe
9,283,282Sustained release polymer► Subscribe
9,539,333Sustained release polymer► Subscribe
6,630,155 Controlled release liquid delivery compositions with low initial drug burst► Subscribe
9,254,307Polymeric delivery formulations of leuprolide with improved efficacy► Subscribe
8,840,916Sustained release polymer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101669900► Subscribe
Germany60141421► Subscribe
Canada2436275► Subscribe
China1474685► Subscribe
European Patent Office1126822► Subscribe
Germany69914787► Subscribe
Denmark1126822► Subscribe
Denmark1322286► Subscribe
Denmark1586309► Subscribe
Denmark2158900► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Express Scripts
QuintilesIMS
Daiichi Sankyo
Chinese Patent Office
Farmers Insurance
Johnson and Johnson
Julphar
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot